Glucose control in diabetes

Diabetes/Metabolism Research and Reviews

Volumn 20, Issue SUPPL. 2, 2004, Pages

  Valeri, Cristina ^a   Pozzilli, Paolo ^b   Leslie, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Bio Medico University   (Italy)

Author keywords

Complications; Control; Genetics; Glycated proteins; Monitoring; Technology

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

AMPUTATION; ATHEROSCLEROSIS; CAPILLARY BLOOD; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MONITORING; MORTALITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSOR; SURVIVAL RATE; URINALYSIS;

BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 11144249856     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.512     Document Type: Review

References (44)

1. Kannel WB, Neaton JD, Wentworth D, et al. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J 1986; 112: 825-836.
2. Stanler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial Stamler. Diabetes Care 1993; 16: 434-444.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
5. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994; 154: 2169-2178.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
7. UKPDS Consortium. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
8. Diabetes Control and Complication Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complication trial. Diabetes 1996; 45: 1289-1298.
9. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1147.
10. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36: 1175-1184.
11. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
12. Andersson DK, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995; 18: 1534-1543.
13. Muggeo M, Verlato G, Bonora E, et al. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia 1995; 38: 672-679.
14. DECODE Study Group, The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
15. Eschwege E, Balkau B. Hyperglycaemia: link to excess mortality. Int J Clin Pract Suppl 2001; 123: 3-6.
16. Balkau B, Forhan A, Eschwege E. Two hours plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris prospective study. Diabetologia 2002; 45: 1224-1230.
17. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003; 46(Suppl. 1): M17-M21. Epub 2002 Nov [07.]
18. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study. Diabetes Care 1999; 22: 920-924.
19. Yum SI, Roe J. Capillary blood sampling for self-monitoring of blood glucose. Diabetes Technol Ther 1999; 1: 29-37.
20. Kuwa K, Nakayama T, Hoshino T, Tominaga M. Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma. Clin Chim Acta 2001; 307: 187-192.
21. Kuwa K, Nakayama T, Hoshino T, Tominaga M. Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma. Clin Chim Acta 2001; 307: 187-192.
22. Choubtum L, Mahachoklertwattana P, Udomsubpayakul U, Preeyasombat C. Accuracy of glucose meters in measuring low blood glucose levels. J Med Assoc Thai 2002; 85(Suppl. 4): S1104-S1110.
23. Pfutzner A, Hermanns N, Schroder S, et al. Cross-sectional investigation on the accuracy of alternate site glucose testing using the Soft-Sense glucose meter. Swiss Med Wkly 2002; 132: 51-57.
24. Ellison JM, Stengmann JM, Colner SL, et al. Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling sites. Diabetes Care 2002; 25: 961-964.
25. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated haemoglobin: a pilot study. Diab Res Clin Pract 1999; 46: 183-190.
26. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose. Diabetes Care 2001; 24: 1858-1862.
27. Chase HP, Kim LM, Owen SL, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 2001; 107: 222-226.
28. Metzger M, Leibowitz G, Wainstein J, Glazer B, Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care 2002; 25: 1185-1191.
29. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated hemoglobin in non-diabetic subjects not related to glycemia. Diabetologia 1990; 33: 208-215.
30. Arnetz BB, Kallner A, Theorell T. The influence of aging on hemoglobin HbA1c. J Gerontol 1982; 37: 648-650.
31. Snieder H, Boomsma DI, van Doornen LJ, Neale MC. Bivariate genetic analysis of fasting insulin and glucose levels. Genetic Epidemiol 2000; 16: 426-446.
32. Snieder H, Sawtell PA, Ross L, Walker J, Spector TD, Leslie RD. HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes 2001; 50: 2858-2863.
33. Ellison TL, Elliott R, Moyses SA. HbA(1c) screening for undiagnosed diabetes in New Zealand. Diabetes Metab Res Rev 2004; (in press) DOI: 10.1002/dmrr.486.
34. Cohen RM, Holmes YR, Chenier TC, Joiner CH. Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and in relation to diabetic nephropathy. Diabetes Care 2003; 26: 163-167.
35. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
36. Nakamura Y, Horii Y, Nishino T, et al. Immunihistochemical localization of advanced glycosylation end products (AGEs) in coronary atheroma and cardiac tissue in diabetes. Am J Pathol 1999; 143: 1649-1656.
37. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of N-eta-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-468.
38. Cerami A, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997; 94: 13 915-13 920.
39. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2001; 99: 15 596-15 601.
40. Leslie RD, Beyan H, Sawtell P, Boehm BO, Spector TD, Snieder H. Level of an advanced glycated end product is genetically determined: a study of normal twins. Diabetes 2003; 52: 2441-2444.
41. Chiarelli F, de Martino M, Mezzetti A, et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 1999; 134: 486-491.
42. Chiarelli F, Catino M, Tumini S, et al. Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr Nephrol 2000; 14: 841-846.
43. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004; 53: 131-142.
44. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955.